pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·Sep 17·1 min read
save

UK parliamentary committees demand probe into cost of US-UK pharma trade deal

Sep 17, 2026·read at Endpoints ↗RegulatoryNegative

Six UK parliamentary committees have written to the relevant watchdog asking for an investigation into the cost of the United Kingdom's pharmaceutical trade agreement with the United States.

The committees say the deal may not be delivering sufficient value for the National Health Service and request greater transparency on pricing structures and any subsidies involved.

Their request could prompt a formal inquiry if the watchdog finds the concerns justified, putting pressure on the government to review the agreement.

source

This writeup was produced by pharmadog from original reporting by Endpoints.

Original headline: “UK government committees call for probe into US pharma deal”

read at Endpoints ↗
77 words · retrieved Sep 17
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

no entities indexed yet

related stories

  • 17h agoAnthropic’s one-person biotech buy; Jake Van Naarden’s dealmaking strategy; and moreEndpoints
  • 1d agoSanofi may seek higher European drug prices, not withhold launches, under Trump dealEndpoints
  • 1d agoGilead CAR-T on partial clinical hold; Agios' PDUFA date pushed backEndpoints
  • 1d agoAstraZeneca says reorg could mean R&D cuts and trials shifted to emerging marketsEndpoints
  • 1d agoAnthropic's Nathan Frey on biopharma partners, M&A and pipelineEndpoints